The Philippine e-cigarette bill, known as Senate Bill 2239 or the "Vaporized Nicotine and Non-Nicotine Product Regulation Bill," aims to regulate the importation, manufacture, sale, packaging, distribution, use and consumption of electronic cigarettes and heated tobacco products (HTP). It is a coordinated version of the lower house bill, House Bill 9007 or the "Non-Combustible Nicotine Delivery Systems Regulation Bill.
Three months after the passage of the bill, "world-renowned experts have signed the "Manila Declaration 2022". The declaration was released on October 28th after the 5th Asian Harm Reduction Forum (AHRF 2022) and aims to provide information and evidence for the World Health Organization (WHO) to control safer nicotine products that are not included in any guidance provided to the signatories and representatives of the Framework Convention on Tobacco Control (FCTC). It also highlights that, despite scientific support for the use of e-cigarettes for smoking cessation, e-cigarette users continue to be marginalized, overlooked, and attacked for their choice.
Personal health rights are considered a fundamental human right. Smoking leads to the vast majority of tobacco-related deaths and illnesses. E-cigarettes are much safer than traditional cigarettes and have helped millions quit smoking. Reducing harm is at the core of international treaty obligations. Bans are only used to protect the cigarette industry. Public health and government reputation are under threat, the statement said.
The document highlights the absurdity of allowing cigarettes to enter the market while prohibiting safer alternatives. It stresses that enabling the free sale of a product that is certain to cause harm in the open market is a criminal act and prohibits or restricts the provision of safer alternatives for adult smokers.
The Asia Harm Reduction Forum (AHRF) held its fifth annual conference on October 28, 2022 in the Philippines, under the theme "Incorporating Harm Reduction into Asian Policy: A Major Victory for Public Health." The conference aimed to build on previous successes and momentum, and as a non-profit, interdisciplinary organization, AHRF seeks to provide information and education on harm reduction, recent scientific research, and public health development. A major focus of the forum was reducing tobacco harm.
Nancy Loucas, the Executive Coordinator of the Coalition of Asia-Pacific Tobacco Harm Reduction Advocates (CAPHRA), has emphasized that the Framework Convention on Tobacco Control (FCTC) has continued to disappoint smokers who want to quit. According to Loucas, providing false information to signatory countries as "guidance" by the WHO Framework Convention on Tobacco Control and its affiliated agencies is dangerous. She believes that the FCTC has already failed and will continue to do so as 8 million adults die every year from unsafe tobacco products.
The Philippine representative of CAPHRA, Clarisse Virgino, has expressed appreciation for Philippine legislators' decision to ultimately include harm reduction in legislation. "The vape law introduced new possibilities for harm reduction alternatives in the country. This is just the first step towards creating a healthier and safer environment for everyone. We hope our legislators will continue to explore different aspects of harm reduction within their mandate to protect the welfare of their citizens," said Virgino.
Statement:
This article is compiled from third-party sources and is intended for industry-related discussions and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is intended solely for industry exchange and research purposes.
The translated article may not fully convey the original message due to limitations in the translation process. Therefore, it is advised to refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan and foreign-related expressions and positions.
The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
